Transplantation of haploidentical stem cells has become a well-established approach, which makes a potential donor available for almost all patients. This review focuses on current results and new strategies, especially in pediatric patients with malignant diseases. CD34 þ positive selection was the most common procedure for graft manipulation in the past years, whereas T and B cell depletion is a promising new method. GVHD could herewith be effectively reduced and primary engraftment was reported in 83-100% of patients after transplantation of high stem cell doses. For patients with ALL in remission, diseasefree survival at 3 years ranged between 22 and 48%. TRM, mainly because of viral infections, was improved by the use of reduced-intensity conditioning (which helped to speed up T cell recovery) and by close monitoring of viral loads and prophylactic/preemptive therapy. The role of donor-derived Ag-specific T cells against viral and fungal antigens is currently under investigation. Patients with active disease at the time of transplantation had a poor outcome and several attempts to improve these results are currently evaluated, such as co-infusion of natural killer cells, co-transplantation of MSC, use of new antileukemic drugs and post-transplant immunotherapy.
Introduction
Transplantation of manipulated hematopoietic stem cells from mismatched related donors has gained wide acceptance in the treatment of children with leukemia and several non-malignant diseases. This now well-established approach makes a potential donor available for each child in need of SCT by using the parents. Indeed, only 25% of children have an HLA-identical sibling, and a suitably matched unrelated donor does not exist or will not be found within an acceptable time frame for a substantial portion of the remaining patients. Several approaches have been evaluated in the past years to solve the major problems of HLA-mismatched transplantation: (1) to overcome the HLA barrier to engraftment, (2) to prevent GVHD by profound depletion of T cells in vitro and/or in vivo and (3) to reduce TRM caused by intensive conditioning regimens and by delayed T cell recovery post transplant. This review focuses on current results and new strategies, especially in pediatric patients.
Graft manipulation procedures
The risk of severe GVHD depends on the degree of HLA disparity, and a rate of up to 90% acute GVHD III-IV was observed in patients receiving unmanipulated marrow grafts from three loci mismatched related donors. 1 Alloreactive donor T cells have been shown to play a major role in mediating GVHD in this setting. Depletion of these cells can effectively prevent clinical symptoms even in the case of full haplotype mismatched donors. Several strategies have been used to minimize the number of donor T cells in the graft:
(1) direct depletion of T cells with soybean lectin agglutination in vitro 2 or with MoAb in vitro and in vivo,
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(2) positive selection of CD34 þ or CD133 þ progenitor cells with immunomagnetic microbeads in vitro, which includes indirect depletion of all other cell types, [4] [5] [6] (3) direct depletion of T cells with antiCD3 coated microbeads, 7 in combination with Ab mediated (antiCD20, rituximab) depletion of B cells in vivo or with CD19 coated microbeads 8 ( Table 1) .
The number or residual T cells in the grafts is crucial and depletion factors in the range of 4-5 log are required. 10, 16 There is clinical evidence that even very low cell numbers (3 Â 10 4 /kg bodyweight) can cause severe GVHD 2 in patients who receive no further post-transplant pharmacological immunosuppression. However, the risk appears to be rather low if a threshold of 5 Â 10 4 T cells per kg is expected in adults. 16 In children, doses between 0.2-5.2 Â 10 4 /kg were given without inducing significant GVHD. 11, 13 In our experience, a threshold of 2.5 Â 10 4 is considered safe, whereas in the case of higher T cell doses, CsA or mycophenolate mofetil prophylaxis is recommended.
In recent years, most groups preferred positive selection as better and more reliable depletion results were achieved with this procedure as compared to lectin agglutination or Ab purging. Moreover, a high rate of EBV-associated lymphoproliferative disease has been reported after transplantation with solely T cell-depleted grafts. 17 The low incidence of EBV-associated lymphoproliferative disease in pediatric patients with CD34 þ or CD133 þ selected grafts was related to the additional indirect depletion of mature B cells harboring the EBV. 5, 9, 11, 13, 18 However, new stem cell markers, targeting CD34 negative progenitors, have questioned whether positive selection procedures will be sufficient to identify early and pluripotent progenitor cells. 7 Further, other immune components such as natural killer (NK) cells, DCs and monocytes are lost during the separation procedure and cannot be used to generate antitumor, antiviral or graft-facilitating effects. /kg NK cells have been infused in ongoing studies. 7, 8, 14, 15 Accurate enumeration of residual T cells after depletion with CD3 reagent is crucial and requires a special multi-gating strategy because of the high number of nucleated cells and low frequency of T cells for flow-cytometric analysis. 20 Another interesting approach is the use of CD6 þ -depleted PBSC together with unmanipulated BM, which has been already utilized in a limited number of pediatric patients. 21 After haploidentical transplantation in adult patients, NK cells have been recently demonstrated to exert remarkable GVL effects in AML but not in ALL. 22 The model to predict such NK alloreactivity is based on certain KIR-ligand mismatches within the HLA class I alleles between donor and recipient and may be appropriate also for childhood AML. Apart from this 'KIR-ligandmismatch' model, the 'receptor-ligand-mismatch' model has been established (based on the occurrence of inappropriate KIRs that do not bind to HLA alleles of the target), which can contribute to a survival advantage, especially in children with ALL. 23 In our institution, criteria for selection of an appropriate donor comprise assessment of receptor-ligand mismatches, CMV status and physical condition.
Engraftment and GVHD
Graft failure can present as the inability to achieve donor cell engraftment ('non-engraftment') or as a severe decrease of the donor-derived hematopoiesis after initial engraftment. 24 Several factors may be involved in this severe complication, such as compromised host marrow microenvironment, 25 infections with herpes viruses, 26 inadequate stem cell numbers 27 or, on the other hand, persistent host immunity, mediated by residual T and NK cells and HLA disparity. 28 It has been shown that CD3 þ /CD8 þ T cells of recipient origin frequently emerge in graft rejection. 29 More recently, the alloreactive specificity of such cells for mismatched HLA class I subtypes as well as specific CD4 þ T cells for HLA class II were demonstrated. 30 It is therefore understandable that HLA mismatches between donor and recipient may increase the incidence of rejection, 31 as may preparative regimens with reduced intensity or T cell depletion of the grafts. 32 To overcome the HLA barrier, most conditioning regimens for haplotransplantation in children were myeloablative and BU or TBI (14.4 or 12 Gy) based. 2, 3, 5, 9, 11, 13, 18 Thiotepa was added by some groups to enhance myeloablation. 12 Alternatively, VP16 was used in patients with acute leukemias. All groups used CY or fludarabine or both as immunosuppressive agents and Ab preparations (antithymocyte globulin and/or OKT3 or Campath) as rejection prophylaxis. The majority of patients received no post-transplant immunosuppression (Table 1) .
Handgretinger and colleagues 8, 15, 33 introduced a new melphalan-based reduced-intensity conditioning regimen (melphalan/Thiotepa/fludarabine/OKT3), which excludes TBI and antithymocyte globulin to reduce organ damage and to improve immune reconstitution and which is evaluated in ongoing studies. þ selected grafts after BU or TBI-based myeloablative regimens. Preliminary results of ongoing studies with melphalan-based reduced-intensity conditioning regimens and T/B cell-depleted grafts show similar or even better engraftment rates (85-91%), 7, 14, 15 probably because of graft facilitating effects of co-transfused alloreactive NK cells. Final and sustained engraftment was achieved after reconditioning and second stem cell donation in 98% of our patients. 36 In particular, an immunoablative reconditioning regimen consisting of TLI, fludarabine and serotherapy, as well as retransplantation with stem cells from a second haploidentical donor other than the first, was well tolerated and resulted in sustained and reliable engraftment. This approach was also used to rescue patients with graft failure after cord blood or matched unrelated donor transplantation and for whom a second donation from the original donor was not available. 29 High median stem cell doses between 11.3 and 24.3 Â 10 6 /kg were infused in several studies according to the megadose concept of Reisner et al. 16 To date, there is no clear clinical evidence for the optimum cell dose, and a wide range of CD34 þ selected progenitors (4.2-58 Â 10 6 /kg) was able to induce successful engraftment. 5, 9, 11, 13, 18, 34 In patients with T and B cell-depleted grafts, cell doses of approximately 2 Â 10 6 /kg resulted in stable engraftment. Frequent analyses of T cell chimerism can help to predict graft rejection, either by PCR analysis of VNTR regions or by flow cytometry of lymphocyte subsets with MoAb against HLA Ags of recipient and donor. 37, 38 In case of increasing autologous signals, (1) cessation of immunosuppression and (2) if necessary, low-dose donor lymphocyte infusions are recommended to restore a complete donor chimerism. 38 Moreover, ongoing studies evaluate the role of co-transplanted MSC in the prevention of graft failure. 34, 39 No rejection occurred in a limited number of patients who received co-transplants of MSC, compared with 15% graft failure in a historical control group. 34 The risk of acute and chronic GVHD was significantly reduced by all mentioned graft manipulation procedures and therefore comparable with that after matched unrelated donor transplantations. The rates ranged between 0-24% (acute GVHDXgrade II) and between 0-19% (chronic) 5, 9, 11, 13, 35, 40 after CD34 or CD133 positive selection and between 36 and 27% (acute GVHDXgrade II) after CD3 depletion and CD20 or CD19 depletion. 7, 14 In contrast to those studies, Chinese and Japanese groups investigated the use of G-CSF primed BM/PBSC without any in vitro T cell depletion on the basis of antithymocyte globulin and post-transplant immunosuppression with 3-4 agents. 41, 42 Considering the large number of infused T-cells, a surprisingly low rate of GVHD was observed (cumulative incidences of 57% (acute GVHD II-IV) and 56% (chronic GVHD)). 41 However, this approach appears to be associated with a higher risk of GVHD than in vitro T-cell depletion methods.
Immune reconstitution and TRM
Two major causes of TRM are endothelial damage/organ toxicity induced by the conditioning itself and delayed T cell reconstitution that may result in severe viral or fungal infections. A prospective study in patients with CD34 þ selected grafts and myeloablative conditioning showed that the median time to normal proliferative responses of T cells was 7-8 months; 43 a median number of 218 CD3 per ml was observed at day 120 in patients with malignant diseases. 8 In another study, T cell recovery was not detected until 5-6 months post transplant. 40 Some factors of influence on reconstitution of T cells have been identified: (1) Serotherapy (type and dosage of the used antibodies). (2) High stem cell doses may contribute to a robust reconstitution and were associated with a more rapid CD3 þ recovery in two studies with children.
9,10 (3) Irradiation as part of the conditioning regimen. Chen et al. 7 compared patients who received a non-TBI, melphalan-based reduced-intensity conditioning with patients after standard TBI/antithymocyte globulin; both groups received CD3-depleted stem cells (plus CD20 depletion in vivo). The non-TBI group showed a significantly faster thymus-dependent T cell recovery, as demonstrated by higher sjTREC counts (signal joint T cell receptor excision circles), TCRVbeta scores and CD3 þ counts, probably caused by reduced damage to organs that generate immune cells. Moreover, different types of graft manipulation procedures appear to have an additional influence, but this effect still remains to be determined. 7, 8 It is widely accepted that severe infections are associated with delayed immune reconstitution post transplant. Interestingly, higher numbers of infectious deaths are reported in adults 44 than in children, probably reflecting an impaired thymic function in older patients. 45 In haplo-SCT with CD34 þ selected stem cells, infections with adenovirus (ADV), CMV and Aspergillus remained a significant cause of mortality in children within the first 6 months post transplant. Incidences of CMV reactivation between 14 and 29% have been reported, leading to lethal infections in 0-8%. 9, 10, 11, 13, 46 ADV has become the most common viral pathogen, with cumulative risks of infection between 8.5 and 29% and infectious deaths between 0 and 17%. 9, 13, 47 Feuchtinger et al. 47 demonstrated that all patients with ADV-associated mortality had no specific T cells, whereas survivors of ADV infections developed a specific T cell immunity against adenoviral Ags. Similar observations in CMV infections underline the potential role of Ag-specific T cells as a sufficient antiviral defense.
In haplo-SCT with CD3-depleted stem cells (plus CD20 depletion in vivo) and reduced-intensity conditioning, viral loads (ADV, CMV, EBV) in peripheral blood were significantly lower than in a CD34 þ selected control group. 7 None of the 22 patients had died of viremia, probably because of the better recovery of thymusdependent T cells and to a stronger NK cell mediated first-line defense. Similar results have been obtained in an interim analysis of our ongoing study with CD3/CD19-depleted stem cells, as no lethal viral infection occurred in 38 patients. 14 Intensive surveillance of viral infections has become an essential component of the management of haplo-SCT, to detect early those patients at risk for systemic disease with a need for preemptive therapy. 48 In our institution, PCR screening for CMV (blood), ADV (stool and, if positive, PCR testing of blood) and BK virus (urine) is performed weekly. Additional antiviral treatment with cidofovir (ADV) or ganciclovir (CMV) will be started immediately in the case of positive PCR findings. In case of resistant infections during insufficient immune reconstitution, adoptive immunotherapy with donor-derived isolated specific T cells should be considered as a new treatment option. Specific T cells against CMV, ADV, EBV or Aspergillusrelated Ags as well as allodepleted donor T cells are evaluated in ongoing clinical trials, and encouraging preliminary results have already been obtained also in haplo-SCT in children. 49, 50 An algorithm for treatment of ADV infections has been reviewed in detail by Feuchtinger et al. 51 Low numbers of specific T cells were isolated after ex vivo stimulation by IFN-g secretion and magnetic microbeads and administered without inducing GVHD. 52 
Outcome and future perspectives
Transplant related mortality could be effectively reduced by improved T cell recovery and close monitoring of viral loads followed by preemptive therapy and by the use of reduced-intensity conditionings, whereas relapse remains the major cause of death.
53 3y-EFS in single center studies with CD34 þ selected grafts were 36 and 48% for ALL (CR1-3) and 18 and 28% for myeloic leukemias (CR1-2); 11,13 a recent collaborative retrospective study showed 3y-EFS of 35% (CR1), 28% (CR2) and 0% (CR3) in patients with ALL. The same study revealed a significantly better outcome with lower relapse rates and TRM for centers performing a higher number of haplotransplants. 35, 54 A preliminary analysis of our ongoing study with CD3/19 depleted grafts showed a 1y-EFS of 70% for acute leukemias in remission. Patients with active disease at time of transplant had an unfavorable outcome with high relapse rates in most studies. Interestingly, Chen et al.
7 demonstrated 2y-EFS of 25% in this high-risk group. Further efforts are warranted to improve the results in patients with high leukemia burden. Ongoing pilot studies address the use of new drugs such as clofarabine (which can induce remissions in otherwise refractory disease) as part of the conditioning regimen and post-transplant immunotherapies, such as administration of cytokines in vivo and infusion of donor-derived effector cells (alloreactive NK cells 55 or T cells) with antileukemic potential. The role of MSC for treatment of GVHD and facilitation of engraftment is under investigation. 34, 39 Moreover, possible graftversus-tumor effects after haplo-SCT are currently evaluated in children with relapsed solid tumors. 15, 56, 57 In summary, haploidentical transplantation has been markedly improved by technical advances and consecutive clinical studies. Further efforts will be necessary to evaluate the advantages and limitations of this interesting approach.
